Profile

Karl-Erik Andersson, M.D., Ph.D.Wake Forest School of Medicine

Karl-Erik Andersson, M.D., Ph.D.

Professor,


Contact Information

Academic: 336-713-1195 | Department: 336-716-2011

Email: keanders@wakehealth.edu

Education & Training

  • M.D., Lund University Fac Med-Sweden, 1968
Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.

Professor, Institute for Regenerative Medicine
Physiology & Pharmacology
Urology

Contact Information

Academic: 336-713-1195 | Department: 336-716-2011

Email: keanders@wakehealth.edu

Recent Publications

Sawada N, Nomiya M, Zarifpour M, Mitsui T, Takeda M, Andersson KE. Melatonin improves erectile function in rats with chronic lower body ischemia. J Sex Med. 2016;13(2):179-186.

Andersson KE. Potential future pharmacological treatment of bladder dysfunction. Basic Clin Pharmacol Toxicol. 2016;():.

Ihara T, Mitsui T, Nakamura Y, Kira S, Miyamoto T, Nakagomi H, Sawada N, Hirayama Y, Shibata K, Shigetomi E, Shinozaki Y, Yoshiyama M, Andersson KE, Nakao A, Takeda M, Koizumi S. The Clock mutant mouse is a novel experimental model for nocturia and nocturnal polyuria. Neurourol Urodyn. 2016;():.

Williams JK, Dean A, Badra S, Lankford S, Poppante K, Badlani G, Andersson KE. Cell vs. chemokine therapy in a nonhuman primate model of chronic intrinsic urinary sphincter deficiency. J Urol. 2016;():.

Andersson KE. Intraprostatic injections for lower urinary tract symptoms treatment. Curr Opin Urol. 2015;25(1):12-18.

Zarifpour M, Nomiya M, Sawada N, Andersson KE. Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. Prostate. 2015;75(3):233-241.

Andersson KE. Mechanisms of ATP release - future therapeutic targets? [editorial]. BJU Int. 2015;115(6):850-851.

Andersson KE. Potential of stem cell treatment in detrusor dysfunction. Adv Drug Deliv Rev. 2015;82-83():117-122.

Nomiya M, Andersson KE, Yamaguchi O. Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Int J Urol. 2015;22(1):40-46.

Andersson KE, Nomiya M, Yamaguchi O. Chronic pelvic ischemia: contribution to the pathogenesis of lower urinary tract symptoms (LUTS): a new target for pharmacological treatment?. Low Urin Tract Symptoms. 2015;7(1):1-8.

Sunagawa M, Wolf-Johnston A, Nomiya M, Sawada N, Andersson KE, Hisamitsu T, Birder LA. Urinary bladder mucosal responses to ischemia. World J Urol. 2015;33(2):275-280.

Guimaraes-Souza NK, Yamaleyeva LM, Lu B, Ramos AC, Bishop CE, Andersson KE. Superoxide overproduction and kidney fibrosis: a new animal model. Einstein (Sao Paulo). 2015;13(1):79-88.

Yamagishi T, Ishizuka O, Imamura T, Yokoyama H, Ogawa T, Kurizaki Y, Nishizawa O, Andersson KE. Alpha1 -adrenergic receptors mediate bladder overactivity induced by cold stress in rats with bladder outlet obstruction. Neurourol Urodyn. 2015;34(3):280-285.

Tu H, Cao N, Gu B, Si J, Chen Z, Andersson KE. Serotonin (5-HT)2A/2C receptor agonist (2,5-dimethoxy-4-idophenyl)-2-aminopropane hydrochloride (DOI) improves voiding efficiency in the diabetic rat. BJU Int. 2015;116(1):147-155.

Andersson KE. Drug therapy of overactive bladder - what is coming next?. Korean J Urol. 2015;56(10):673-679.

Burmeister D, Bishwokarma B, AbouShwareb T, Olson J, Herco M, Tan J, Andersson KE, Christ G. The potential utility of non-invasive imaging to monitor restoration of bladder structure and function following subtotal cystectomy (STC). BMC Urol. 2015;15(1):103.

Fullhase C, Hennenberg M, Sandner P, Strittmatter F, Niedworok C, Bauer RM, Gratzke C, Soler R, Stief C, Andersson KE. Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor. Neurourol Urodyn. 2015;34(8):787-793.

Kullmann FA, Birder LA, Andersson KE. Translational research and functional changes in voiding function in older adults. Clin Geriatr Med. 2015;31(4):535-548.

Salemi S, Tremp M, Plock JA, Andersson KE, Gobet R, Sulser T, Eberli D. Differentiated adipose-derived stem cells for bladder bioengineering. Scand J Urol. 2015;49(5):407-414.

Andersson KE. What's going on the the overactive bladder arena?. Drugs Future. 2015;40(12):827-834.

Andersson KE, McCloskey KD. Lamina propria: the functional center of the bladder?. Neurourol Urodyn. 2014;33(1):9-16.

Chapple CR, Abrams P, Andersson KE, Radziszewski P, Masuda T, Small M, Kuwayama T, Deacon S. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome. J Urol. 2014;191(1):253-260.

Yamaguchi O, Nomiya M, Andersson KE. Functional consequences of chronic bladder ischemia. Neurourol Urodyn. 2014;33(1):54-58.

Fullhase C, Campeau L, Sibaev A, Storr M, Hennenberg M, Gratzke C, Stief C, Hedlund P, Andersson KE. Bladder function in a cannabinoid receptor type 1 knockout mouse. BJU Int. 2014;113(1):144-151.

Andersson KE. Bladder underactivity [editorial]. Eur Urol. 2014;65(2):399-401.

Campeau L, Soler R, Sittadjody S, Pareta R, Nomiya M, Zarifpour M, Opara EC, Yoo JJ, Andersson KE. Effects of allogeneic bone marrow derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson disease. J Urol. 2014;191(3):850-859.

Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65(5):981-990.

Zarifpour M, Sandberg J, Abolbashari M, Vadhavkar M, Kelkar S, Mohs A, Marini F, Andersson KE, Christ G. Characterization of functional bladder regeneration in mice [abstract]. Neurourol Urodyn. 2014;33(2):186.

Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5.

Campeau L, Fullhase C, Sawada N, Gratzke C, Hedlund P, Howlett AC, Andersson KE. Characterization of bladder function in a cannabinoid receptor type 2 knockout mouse in vivo and in vitro. Neurourol Urodyn. 2014;33(5):566-570.

Colaco M, Koslov DS, Keys T, Evans RJ, Badlani GH, Andersson KE, Walker SJ. Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome. J Urol. 2014;192(4):1123-1129.

Kim J, Andersson KE, Jackson JD, Lee SJ, Atala A, Yoo JJ. Downregulation of metabolic activity increases cell survival under hypoxic conditions: potential applications for tissue engineering. Tissue Eng Part A. 2014;20(15-16):2265-2272.

Nomiya M, Yamaguchi O, Akaihata H, Hata J, Sawada N, Kojima Y, Andersson KE. Progressive vascular damage may lead to bladder underactivity in rats. J Urol. 2014;191(5):1462-1469.

Andersson KE. The many faces of impaired bladder emptying. Curr Opin Urol. 2014;24(4):363-369.

Andersson KE. Current and future drugs for treatment of MS-associated bladder dysfunction. Ann Phys Rehabil Med. 2014;57(5):321-328.

Hanna-Mitchell AT, Kashyap M, Chan WV, Andersson KE, Tannenbaum C. Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013. Neurourol Urodyn. 2014;33(5):611-617.

Kunit T, Gratzke C, Schreiber A, Strittmatter F, Waidelich R, Rutz B, Loidl W, Andersson KE, Stief CG, Hennenberg M. Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. Am J Physiol Renal Physiol. 2014;307(7):F823-F832.

Andersson KE. The use of pharmacotherapy for male patients with urgency and stress incontinence. Curr Opin Urol. 2014;24(6):571-577.

Williams JK, Andersson K. A comparison of cellular and acellular (chemokine) therapy in a primate model of urinary sphincter deficiency [abstract]. Neurourol Urodyn. 2014;33(6):835-836.

Drumm BT, Koh SD, Andersson KE, Ward SM. Calcium signalling in Cajal-like interstitial cells of the lower urinary tract. Nat Rev Urol. 2014;11(10):555-564.

Jackson JR, Kim N, Kim J, Andersson KE, Yoo J, Atala A. Induction and maintenance of cellular hypometabolsm for improved tissue survival for reconstructive procedures [abstract]. J Am Coll Surg. 2014;219(3 Suppl):S142.

Tremp M, Salemi S, Largo R, Andersson KE, A Plock J, Aboushwareb T, Sulser T, Eberli D. Adipose-derived stem cells (ADSCs) and muscle precursor cells (MPCs) for the treatment of bladder voiding dysfunction. World J Urol. 2014;32(5):1241-1248.

Gang W, Hongjian T, Jasheng C, Jiemin S, Zhong C, Yuemin X, Baojun G, Andersson KE. The effect of the 5-HT7 serotonin receptor agonist, LP44, on micturition in rats with chronic spinal cord injury. Neurourol Urodyn. 2014;33(7):1165-1170.

Andersson KE. Effects of chronic pelvic ischemia on bladder function [abstract]. Acta Physiol (Oxf). 2014;211(Suppl 696):52-53.

Walker SJ, Colaco M, Koslov DS, Keys T, Evans RJ, Badlani GH, Andersson KE. Transcriptome analysis of bladder biopsy from interstitial cystitis/bladder pain syndrome patients. Genom Data. 2014;2():366-368.

Gratzke C, Andersson K-E. Alpha-blockers and antimuscarinics for male lower urinary tract symptoms: the search goes on [editorial]. Eur Urol. 2013;63(1):166-167.

Hood B, Andersson K-E. Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. Int J Urol. 2013;20(1):21-27.

Ishizuka O, Imamura T, Kurizaki Y, Nishizawa O, Andersson KE. Male lower urinary tract symptoms and alpha1D-adrenoceptors. Int J Urol. 2013;20(1):73-78.

Kurizaki Y, Ishizuka O, Imamura T, Ishikawa M, Ichino M, Ogawa T, Nishizawa O, Andersson KE. Relationship between expression of beta3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol Urodyn. 2013;32(1):88-91.

Ochodnicky P, Uvelius B, Andersson KE, Michel MC. Autonomic nervous control of the urinary bladder. Acta Physiol (Oxf). 2013;207(1):16-33.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.

Professor, Institute for Regenerative Medicine
Physiology & Pharmacology
Urology

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.